Covid-19 roundup: J&J en­ters PhI­II with a two-dose reg­i­men to play safe; As­traZeneca, Ox­ford tout promis­ing da­ta in el­der­ly

John­son & John­son had the first sin­gle-dose Covid-19 vac­cine to en­ter Phase III tri­als — but to be cau­tious, the phar­ma is launch­ing a sec­ond Phase III study eval­u­at­ing the can­di­date in a two-dose reg­i­men.

“Janssen’s COVID-19 vac­cine pro­gram has been de­signed to be ex­treme­ly thor­ough and dri­ven by sci­ence,” the com­pa­ny an­nounced on Sun­day. “As such, we are in­ves­ti­gat­ing mul­ti­ple dos­es and dos­ing reg­i­mens to eval­u­ate their long-term ef­fi­ca­cy.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER